Drug class review : final report update 5, HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin

The Resource Drug class review : final report update 5, HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin
Label
Drug class review : final report update 5, HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin
Title remainder
final report update 5
Title part
HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin
Statement of responsibility
M.E. Beth Smith ... [et al.] ; Drug Effectiveness Review Project, Oregon Evidence-based Practice Center, Oregon Health & Science University
Title variation
HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin
Contributor
Subject
Language
  • eng
  • eng
Summary
In the United States, coronary heart disease and cardiovascular disease account for nearly 40% of all deaths each year. Coronary heart disease continues to be the leading cause of mortality and a significant cause of morbidity among North Americans. In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia
Member of
Additional physical form
Issued also online.
Cataloging source
DNLM
Index
no index present
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
Series statement
Drug class reviews

Context

Context of Drug class review : final report update 5, HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin

Work of

Structured data from the Bibframe namespace is licensed under the Creative Commons Attribution 4.0 International License by Sydney Jones Library, University of Liverpool. Additional terms may apply to data associated with third party namespaces.